Lenacapavir: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

22 March 2026

10 March 2026

  • curprev 19:1019:10, 10 March 2026‎ Ostermayer talk contribs‎ 11,940 bytes +11,940‎ Created page with "Lenacapavir is a first-in-class HIV capsid inhibitor developed by Gilead Sciences. It is the first antiretroviral that targets the HIV-1 capsid protein (p24), interfering with multiple stages of viral replication rather than a single enzyme.<ref name="Paik2022">Paik J. Lenacapavir: first approval. ''Drugs''. 2022;82(14):1499-1504. doi:10.1007/s40265-022-01786-0</ref> It is available as an oral tablet and subcutaneous injection, with the injectable formulation designe..."
Retrieved from "https://www.wikem.org/wiki/Lenacapavir"